Trial of atacicept (a fusion protein against the TACI receptor) showed a trend toward clinical improvement in moderate SLE [ 66 ], yet phase II trial of this drug in lupus nephritis was suspended due to high risk of severe infections. 6.
← all excerpts
Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.
1
—
—